Back to Search Start Over

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States.

Authors :
Zanni, Markella V
Zanni, Markella V
Foldyna, Borek
McCallum, Sara
Burdo, Tricia H
Looby, Sara E
Fitch, Kathleen V
Fulda, Evelynne S
Autissier, Patrick
Bloomfield, Gerald S
Malvestutto, Carlos D
Fichtenbaum, Carl J
Overton, Edgar T
Aberg, Judith A
Erlandson, Kristine M
Campbell, Thomas B
Ellsworth, Grant B
Sheth, Anandi N
Taiwo, Babafemi
Currier, Judith S
Hoffmann, Udo
Lu, Michael T
Douglas, Pamela S
Ribaudo, Heather J
Grinspoon, Steven K
Zanni, Markella V
Zanni, Markella V
Foldyna, Borek
McCallum, Sara
Burdo, Tricia H
Looby, Sara E
Fitch, Kathleen V
Fulda, Evelynne S
Autissier, Patrick
Bloomfield, Gerald S
Malvestutto, Carlos D
Fichtenbaum, Carl J
Overton, Edgar T
Aberg, Judith A
Erlandson, Kristine M
Campbell, Thomas B
Ellsworth, Grant B
Sheth, Anandi N
Taiwo, Babafemi
Currier, Judith S
Hoffmann, Udo
Lu, Michael T
Douglas, Pamela S
Ribaudo, Heather J
Grinspoon, Steven K
Source :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America; vol 76, iss 2, 323-334; 1058-4838
Publication Year :
2023

Abstract

BackgroundAmong people with HIV (PWH), sex differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, or relationships therein.MethodsREPRIEVE, a primary ASCVD prevention trial, enrolled antiretroviral therapy (ART)-treated PWH. At entry, a subset of US participants underwent coronary computed tomography angiography (CTA) and immune phenotyping (n = 755 CTA; n = 725 CTA + immune). We characterized sex differences in coronary plaque and immune/inflammatory biomarkers and compared immune-plaque relationships by sex. Unless noted otherwise, analyses adjust for ASCVD risk score.ResultsThe primary analysis cohort included 631 males and 124 females. ASCVD risk was higher among males (median: 4.9% vs 2.1%), while obesity rates were higher among females (48% vs 21%). Prevalence of any plaque and of plaque with either ≥1 visible noncalcified portion or vulnerable features (NC/V-P) was lower among females overall and controlling for relevant risk factors (RR [95% CI] for any plaque: .67 [.50, .92]; RR for NC/V-P: .71 [.51, 1.00] [adjusted for ASCVD risk score and body mass index]). Females showed higher levels of IL-6, hs-CRP, and D-dimer and lower levels of Lp-PLA2 (P < .001 for all). Higher levels of Lp-PLA2, MCP-1, and oxLDL were associated with higher plaque (P < .02) and NC/V-P prevalence, with no differences by sex. Among females but not males, D-dimer was associated with higher prevalence of NC/V-P (interaction P = .055).ConclusionsAmong US PWH, females had a lower prevalence of plaque and NC/V-P, as well as differences in key immune/inflammatory biomarkers. Immune-plaque relationships differed by sex for D-dimer but not other tested parameters. Clinical Trial Registration. ClinicalTrials.gov; identifier: NCT0234429 (date of initial registration: 22 January 2015).

Details

Database :
OAIster
Journal :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America; vol 76, iss 2, 323-334; 1058-4838
Notes :
application/pdf, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol 76, iss 2, 323-334 1058-4838
Publication Type :
Electronic Resource
Accession number :
edsoai.on1391587404
Document Type :
Electronic Resource